<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630277</url>
  </required_header>
  <id_info>
    <org_study_id>ELYSIAN</org_study_id>
    <nct_id>NCT02630277</nct_id>
  </id_info>
  <brief_title>Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN</brief_title>
  <acronym>ELYSIAN</acronym>
  <official_title>Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept Injection (ELYSIAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valley Retina Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valley Retina Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of intravitreal aflibercept injection in the regression of&#xD;
      retinal neovascularization secondary to high-risk PDR.&#xD;
&#xD;
      To characterize baseline/post-induction/maintenance levels of proinflammatory mediators in&#xD;
      patients with high-risk PDR&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate two dosing regimens (monthly and PRN following a loading dose) for&#xD;
      treatment of PDR with intravitreal aflibercept injection. Additionally, the study will&#xD;
      identify biomarker mediators in vitreous fluid present at baseline in patients with PDR and&#xD;
      will track over the course of a year their profile changes in response to these two dosing&#xD;
      regimens. The treatment regimens will provide information on the biomarker profile with a&#xD;
      monthly regimen as well as with a variable regimen. Furthermore, biomarker mediators that may&#xD;
      be associated with anti-VEGF responders and non-responders may also be identified. 105&#xD;
      biomarker mediators (cytokines/chemokines) which have been identified as playing a role in&#xD;
      PDR in published studies will be profiled in patients with PDR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess ocular and non-ocular adverse events</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1:1 Intravitreal Aflibercept Injection once every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal of Aflibercept once every 4 weeks for 4 months then as needed (PRN)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Intravitreal Aflibercept Injection 2.0 mg</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eligible eyes will have active PDR with high risk characteristics (HRC) as defined by&#xD;
             the DRS. All eyes must meet at least one or both of the following criteria:&#xD;
&#xD;
               -  Any neovascularization of the disc (NVD) + vitreous hemorrhage&#xD;
&#xD;
               -  Mild neovascularization of the disc (NVD) of at least 1/2 to 1/3 disc area as&#xD;
                  shown in standard photograph 10A of the DRS&#xD;
&#xD;
               -  Moderate neovascularization of the retina elsewhere (NVE) of at least 1/2 disc&#xD;
                  area as shown in standard photograph 7 of the DRS + vitreous hemorrhage2.&#xD;
                  Patient's study eye must be treatment naïve; no history of intravitreal&#xD;
                  anti-angiogenic treatment, intravitreal steroid treatment, or any laser treatment&#xD;
                  to study eye&#xD;
&#xD;
          2. 18 years or older males and females with a history of diabetes mellitus and ability to&#xD;
             sign informed consent&#xD;
&#xD;
          3. ETDRS visual acuity score greater than or equal to 24 letters (approximately 20/320)&#xD;
             and less than or equal to 85 letters (approximately 20/20) by the ETDRS visual acuity&#xD;
             protocol at the screening visit&#xD;
&#xD;
          4. Eyes with mild pre-retinal hemorrhage or mild vitreous hemorrhage that does not&#xD;
             interfere with clear visualization of the macula and optic disc are eligible for this&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria will be excluded from this study:&#xD;
&#xD;
          1. Presence of moderate or dense PRH or VH that prevents clear visualization of the&#xD;
             macula and/or optic disc&#xD;
&#xD;
          2. Presence of either:&#xD;
&#xD;
               -  Significant epiretinal membranes involving the macula, or&#xD;
&#xD;
               -  Proliferative diabetic membranes along the major retinal arcades that are&#xD;
                  extensive enough to cause either:&#xD;
&#xD;
               -  Significant vitreomacular traction or&#xD;
&#xD;
               -  Significant impairment in visual acuity&#xD;
&#xD;
               -  Presence of any tractional retinal detachment&#xD;
&#xD;
               -  Severe ischemia involving the foveal avascular zone (≥1 disc area) as determined&#xD;
                  by fluorescein angiography performed at the initial screening visit&#xD;
&#xD;
               -  Significant media opacity (due to cornea, anterior chamber, or lens) precluding&#xD;
                  clear visualization of the macula or optic disc&#xD;
&#xD;
               -  Presence of neovascular glaucoma with or without hyphema&#xD;
&#xD;
               -  Previous treatment with intravitreal steroid injections in the study eye&#xD;
&#xD;
               -  Previous treatment with topical anti-inflammatory medications in the study eye&#xD;
&#xD;
               -  Previous treatment with peribulbar steroid injections in the study eye&#xD;
&#xD;
               -  Previous PRP/focal laser treatment in the study eye&#xD;
&#xD;
               -  History of vitreoretinal surgery in the study eye&#xD;
&#xD;
               -  Previous treatment with anti-angiogenic drugs in either eye&#xD;
&#xD;
               -  History of idiopathic or autoimmune uveitis in either eye&#xD;
&#xD;
               -  Active ocular inflammation (including trace or above) in the study eye&#xD;
&#xD;
               -  Structural damage to the center of the macula in the study eye that is likely to&#xD;
                  preclude improvement in VA following the resolution of macular edema, including&#xD;
                  atrophy of the retinal pigment epithelium, subretinal fibrosis, or organized&#xD;
                  hard-exudate plaque&#xD;
&#xD;
               -  Ocular disorders in the study eye that may confound interpretation of study&#xD;
                  results, including retinal vascular occlusion, retinal detachment, macular hole,&#xD;
                  or CNVM of any cause&#xD;
&#xD;
               -  Concurrent disease in the study eye that would compromise VA or require medical&#xD;
                  or surgical intervention during the study period&#xD;
&#xD;
               -  Cataract surgery in the study eye, yttrium-aluminum-garnet (YAG) laser&#xD;
                  capsulotomy, or any other intraocular surgery&#xD;
&#xD;
               -  Aphakia or absence of the posterior capsule in the study&#xD;
&#xD;
               -  Uncontrolled glaucoma or previous filtration surgery in the study eye&#xD;
&#xD;
               -  Evidence at examination of infectious blepharitis, keratitis, scleritis or&#xD;
                  conjunctivitis in either eye or current treatment for serious systemic infection&#xD;
&#xD;
               -  History of cerebral vascular accident or myocardial infarction within 3 months&#xD;
                  prior to Day 1&#xD;
&#xD;
               -  Participation in an investigational trial within 30 days prior to screening that&#xD;
                  involved treatment with any drug (excluding vitamins and minerals) or device&#xD;
&#xD;
               -  Pregnancy (positive pregnancy test) or lactation Sexually active men* or women of&#xD;
                  childbearing potential** who are unwilling to practice adequate contraception&#xD;
                  during the study (adequate contraceptive measures include stable use of oral&#xD;
                  contraceptives or other prescription pharmaceutical contraceptives for 2 or more&#xD;
                  menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal&#xD;
                  ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or&#xD;
                  diaphragm plus contraceptive sponge, foam, or jelly)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor H Gonzalez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victor H. Gonzalez, MD</last_name>
    <phone>956-631-8875</phone>
    <phone_ext>118</phone_ext>
    <email>research@vritx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yesenia Salinas, MA</last_name>
    <phone>956-631-8875</phone>
    <phone_ext>137</phone_ext>
    <email>ysalinas@vritx.com</email>
  </overall_contact_backup>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proliferative Diabetic Retinopathy</keyword>
  <keyword>High Risk PDR</keyword>
  <keyword>aflibercept</keyword>
  <keyword>regression of retinal neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

